title: Alpha1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.
abstract: The effect of prolonged administration of the norepinephrine-mimicking agent metaraminol, the alpha1-adrenergic agonist phenylephrine and the alpha2-adrenergic agonist clonidine on the incidence of gastric cancers induced by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), the ornithine decarboxylase activity of the gastric cancer and the labeling index of the gastric mucosa were investigated in Wistar rats. Rats received s.c. injections of metaraminol, phenylephrine or clonidine every other day after 20 weeks of oral treatment with MNNG. At week 52, administration of metaraminol and phenylephrine at the higher dose significantly increased the incidence of gastric cancers, the ornithine decarboxylase activity of the gastric cancers and the labeling index of the antral epithelial cells. Administration of phenylephrine at the lower dose and clonidine at both doses had no significant effect on the incidence of gastric cancers, the ornithine decarboxylase activity of the gastric cancers or the labeling index of the gastric mucosa. Our results suggest that adrenoreceptor stimulation enhances gastric carcinogenesis and that such enhancement is mediated through alpha1-adrenoceptors without alpha2-adrenoceptor involvement.
authors.affiliation: Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Tatsuta
authors.forename: H
authors.initials: H
authors.lastname: Iishi
authors.forename: M
authors.initials: M
authors.lastname: Baba
authors.forename: H
authors.initials: H
authors.lastname: Yano
authors.forename: N
authors.initials: N
authors.lastname: Sakai
authors.forename: H
authors.initials: H
authors.lastname: Uehara
authors.forename: R
authors.initials: R
authors.lastname: Hirasawa
authors.forename: A
authors.initials: A
authors.lastname: Nakaizumi
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D002273:Carcinogens; D003000:Clonidine / Q000494:pharmacology; D005753:Gastric Mucosa / Q000187:drug effects / Q000201:enzymology / Q000473:pathology*; D015994:Incidence; D008297:Male; D008680:Metaraminol / Q000494:pharmacology; D008769:Methylnitronitrosoguanidine / Q000633:toxicity*; D008940:Mitotic Index / Q000187:drug effects; D009955:Ornithine Decarboxylase / Q000032:analysis; D010656:Phenylephrine / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000502:physiology*; D018341:Receptors, Adrenergic, alpha-2 / Q000502:physiology; D013274:Stomach Neoplasms / Q000139:chemically induced* / Q000201:enzymology / Q000473:pathology
chemical_list: D000316:Adrenergic alpha-Agonists; D002273:Carcinogens; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; D008769:Methylnitronitrosoguanidine; D010656:Phenylephrine; D008680:Metaraminol; D009955:Ornithine Decarboxylase; D003000:Clonidine